Commodity Channel Index
|Bid||24.64 x 800|
|Ask||27.73 x 1100|
|Day's Range||24.23 - 25.48|
|52 Week Range||12.39 - 30.41|
|Beta (5Y Monthly)||1.79|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 04, 2020 - Aug 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||28.36|
Denali Therapeutics Inc. (DNLI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
Investors in Denali Therapeutics Inc. (NASDAQ:DNLI) had a good week, as its shares rose 9.6% to close at US$23.89...
SOUTH SAN FRANCISCO, May 07, 2020 -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross.
Denali Therapeutics Inc. (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
In the span of eight days last month, CytomX Therapeutics Inc. landed a collaboration with Astellas Pharma and captured a $40 million milestone payment from AbbVie Inc. as it preps for a mid-stage cancer clinical trial. “It’s a challenging time for our industry,” said CytomX President and CEO Sean McCarthy.
“In these unprecedented times, our resolve to defeat degeneration is undiminished and our top priority is to ensure the health and safety of our employees, community, partners and clinical trial participants,” said Ryan Watts, Ph.D., CEO. For the ongoing DNL151 Phase 1 and Phase 1b trials, enrollment of additional healthy volunteers and patients at higher doses has been paused due to the COVID-19 pandemic. Denali is analyzing available data from these trials and is on track to select either DNL201 or DNL151 by mid-2020 to progress into Phase 2/3 trials.
It's been a mediocre week for Denali Therapeutics Inc. (NASDAQ:DNLI) shareholders, with the stock dropping 19% to...
Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -5.66% and -70.26%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2020 -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered.
If you want a stock market bet that’s 74% likely to lose money, try investing in high-flying stock that sells for 100 times revenue or more Continue reading...
Chief Medical Officer and Head of Development Company: Denali Therapeutics HQ: South San Francisco Years at company: 5 Career turning point: Switching from clinical medicine to research and moving into a management role at Genentech Advice: Women need to be very intentional with networking, Ho says. “I always encourage people to not apologize for the things they do outside of work, be proud of them, talk about them at work and incorporate them into your work life balance.” Carole Ho’s wending career path to biotech startup Denali Therapeutics brought big risks — and big rewards. In 2002, she had just finished her residency in neurology at Massachusetts General Hospital and Brigham and Women’s Hospital for Harvard Medical School when she decided to chance it all and move west to work in a lab at Stanford University.
Denali Therapeutics Inc. (DNLI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
Aimmune's (AIMT) Palforzia is the first medicine to receive an FDA nod for treating patients with peanut allergy. Shares rise in pre-market trading.
SOUTH SAN FRANCISCO, Calif., Jan. 31, 2020 -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the closing of its upsized underwritten public offering of 9,000,000.
Vertex (VRTX) rides high on earnings and revenue beat in Q4. The company provides solid outlook for 2020 resulting in the shares to go up in after-hours trading.
Denali Therapeutics Inc. (DNLI) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Intercept (ICPT) closes enrollment in late-stage study evaluating obeticholic acid for the treatment of compensated cirrhosis due to nonalcoholic steatohepatitis.
Once again, the world is gripped by uncertainty. Fear of an international outbreak of coronavirus, on top of recent worrisome developments between the US and Iran, have spooked investors, sending all three major indexes down over the last week.However, no matter the global outlook, one thing remains certain; investors are still in the game, on the lookout for the best opportunities the market presents. As it happens, if you know where to look, a world teetering precariously on the edge often presents specific investment opportunities.With this in mind, we pulled up two of Goldman Sachs’ recent stock picks which the renowned investment bank thinks can soar in the coming months. Using TipRanks’ Stock Comparison tool, we were able to read the fine print on what 2020 has in store for the two tickers. Let’s take a closer look.Denali Therapeutics Inc. (DNLI)Denali Therapeutics has started off 2020 with a bang. The neurodegenerative disease-focused biotech is up by 34 % year-to-date. The reason for the surge? The company, which is developing a broad portfolio of candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, released an update on the pipeline’s progress. The market, in return, liked what it saw.Among the good news was the data in a Phase 1b trial of LRRK2 inhibitor DNL201, the company’s candidate for the treatment of Parkinson’s disease. The results exhibited "high levels of target and pathway engagement and improvement of lysosomal biomarkers." Additionally, a Phase 1b study of fellow Parkinson candidate and LRRK2 inhibitor, DNL151, exhibited "high levels of target and pathway engagement and modulation of lysosomal biomarkers in healthy volunteers." Both drugs met biomarker goals and were generally well tolerated.Goldman Sachs’ Salveen Richter thinks the safety proﬁle of DNL201 and DNL151 should “ease investor concern regarding potential LRRK2 mediated peripheral/pulmonary toxicities.”The 5-star analyst further added, “While we are cognizant drug development in neurodegenerative diseases has historically been challenging, we believe DNLI’s biomarker-driven approach to establish target/pathway engagement and patient phenotyping (selecting the appropriate patients) will lead to an increased likelihood of clinical success.”Richter thinks the key driver for DNLI in 2020, though, is Denali’s blood brain barrier (BBB) Transport Vehicle (TV) platform. The analyst expects biomarker proof-of-concept results from Phase 1/2 DNL310 in Hunter syndrome by late-2020. Based on pre-clinical data, Richter is confident in the outcome.The analyst said, “We are optimistic that DNL310 will effectively transport the missing IDS protein across the BBB, at therapeutically relevant doses, and demonstrate a reduction (over 50% is the bar) in CSF glycosaminoglycans (GAG) from baseline.”What does it all mean, then? It means Richter upgraded her rating on Denali from Neutral to Buy. The upgrade comes with a bump of the price target, too, up from $20 to $37. The new figure indicates possible upside of a rousing 58%. (To watch Richter’s track record, click here)The Street is also enthusiastic. 4 Buy ratings and 1 Hold add up to a Strong Buy consensus rating. With an average price target of $30.60, analysts expect Denali to add 34% to its share price over the coming 12 months. (See Denali stock analysis on TipRanks) Sibanye Gold (SBGL)Even people with a distinct lack of interest in the movements of financial markets know that in times of uncertainty, investors often turn to the safe haven of gold. The current global climate, then, is good news for gold and other precious metals companies such as Sibanye-Stillwater. The company is South Africa’s largest individual producer of the precious commodity. It’s also one of the world’s ten largest gold producers, and the third largest producer of palladium and platinum. Sibanye’s diversification has been a sound strategy, as the company is not reliant on the sharp movements of just one commodity’s price.Sibanye stock soared dramatically in 2019, rising by over 250% throughout the year; the surge was driven by commodity pricing, the consummation of a protracted acquisition and resolution of a long strike at one of its mining assets. The company boasts a considerably improved balance sheet, too. Sibanye’s net debt was reduced to $1.5 billion by the end of last year’s second quarter, the lowest it has been since Sibanye acquired Stillwater in mid-2017.According to Goldman Sachs’ Eugene King, there are several tailwinds which could see 2019’s market performance extend into 2020. The analyst cites strong PGM (platinum group metals) drivers, continued deleveraging, shareholder returns and a compelling valuation even after the recent rally in PGMs, as catalysts. King forecasts “an above-peer 2020E FCF yield of 20% all offered at a 23% discount to peer 2020E EV/EBITDA valuations.”The analyst said, “While the rally in the broad space has been signiﬁcant, drivers for Palladium and Rhodium remain purely fundamental with no short-term reversal in sight… We believe spot prices are unlikely to pull back meaningfully, enabling continued deleveraging by SGL… With the majority of its operations in SA, SGL stands to gain from a weaker rand. While power stability issues (Eskom) are a risk to earnings, this would likely be offset by a reactive move in PGM prices.”All the above reasons led King to keep his Buy rating on Sibanye. The analyst’s price target comes in at $14 and implies upside potential of 36%. (To watch King’s track record, click here)Adding to the good news, SBGL earns a Smart Score of an 8 out of 10 from TipRanks. The metric uses 8 key factors to help determine the strength of an investment opportunity. (See Sibanye stock analysis on TipRanks)
Incyte (INCY) posts positive top-line results from late-stage TRuE-AD2 study on ruxolitinib cream to treat adolescent and adult patients with atopic dermatitis. The study achieves its main goal.
Denali Therapeutics Inc. (DNLI) today announced the pricing of its underwritten public offering of 7,826,087 shares of its common stock at a price to the public of $23.00 per share. All of the shares are to be sold by Denali Therapeutics. In addition, Denali Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,173,913 shares of its common stock.
AVEO releases results from a phase Ib study on ficlatuzumab in combination with nab-paclitaxel and gemcitabine for treating advanced pancreatic cancer. Shares inch up.